Top in cardiology: Apple Watch app; topline data on dapagliflozin
At Heart Rhythm 2022, researchers reported that applying an artificial intelligence to an Apple Watch ECG can detect left ventricular dysfunction in a nonclinical setting.
The findings were based on a proof-of-concept study that included 2,454 patients. It was the top story in cardiology last week.
Another top story covered the topline findings from the phase 3 DELIVER trial, which showed that dapagliflozin (Farxiga; AstraZeneca) reduced both cardiovascular mortality and worsening heart failure in patients with heart failure with mildly reduced or preserved ejection fraction.
Read these and more top stories in cardiology below:
Apple Watch app, using AI, identifies left ventricular dysfunction
Applying artificial intelligence to an Apple Watch ECG can reliably and safely identify left ventricular dysfunction in a nonclinical setting, researchers reported in a proof-of-concept study. Read more.
DELIVER topline results: Dapagliflozin reduces CV death, worsening HF in EF more than 40%
Topline findings from the phase 3 DELIVER trial show dapagliflozin significantly reduced risk for cardiovascular death or worsening heart failure compared with placebo in adults heart failure with mildly reduced or preserved ejection fraction, AstraZeneca announced. Read more.
Fast-acting nasal spray safe for self-treatment of paroxysmal supraventricular tachycardia
A fast-acting nasal spray was safe and effective for patients self-treating for repeated episodes of paroxysmal supraventricular tachycardia during long-term follow-up, according to findings from the open-label NODE-302 study. Read more.
mRNA technology may have potential to repair, regenerate cardiac tissue
Tissue regeneration has been achieved in certain parts of the body, but not the heart. That could change if a novel therapeutic derived from messenger RNA succeeds. Read more.
Subcutaneous ICD reduces rate of major lead-related complications: ATLAS
Among patients who received implantable cardioverter defibrillator therapy, a subcutaneous vs. transvenous approach reduced major lead-related complications by 92% with no loss in device performance, according to data from the ATLAS trial. Read more.